While therapeutic monoclonal antibodies (mAbs) have been on the market for over 25 years, it wasn’t until recently that the production of these essential biologics began to move away from traditional ...

Biopharma’s ongoing quest to develop COVID-19 drugs and vaccines, plus growing industry demand for producing various types of new therapies, are fueling the $1.5-billion expansion of manufacturing ...